Connect Biopharma initiated with a Buy at Lake Street

Lake Street analyst Thomas Flaten initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $9 price target Shares have recently gained traction in the market in recognition of the upcoming Seabreeze STAT readouts and the upside they may deliver to shareholders, argues the analyst, who sees “significant headroom for shares beyond today” ahead of readouts due in the first half of 2026 and as the long-term potential of rademikibart “becomes more fully understood.”